Brief: In8bio Announces FDA Clearance To Initiate Phase 2 Clinical Trial Of INB-400 For Glioblastoma
08/12/2022 12:45
Dec 8 (Reuters) - IN8BIO, Inc. INAB.O :
* IN8BIO ANNOUNCES FDA CLEARANCE TO INITIATE A PHASE 2
CLINICAL
TRIAL OF INB-400 GAMMA-DELTA T CELLS FOR GLIOBLASTOMA
* IN8BIO, INC. - PHASE 2 CLINICAL TRIAL INITIATION EXPECTED
IN
2023
Source text for Eikon: ID:nGNX2GBTSt
Further company coverage: INAB.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on IN8bio
See all newsIN8bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: IN8BIO - Enters Capital On Demand Sales Agreement With Jonestrading For ATM Offering
IN8bio Q1 net loss narrows as R&D expenses fall